{
  "schemaType": "LegalCase",
  "title": "Hernia Mesh",
  "shortName": "Hernia Mesh",
  "slug": "hernia-mesh",
  "canonicalUrl": "https://tortsignals.lawtegic.solutions/torts/hernia-mesh",
  "description": "Multiple hernia mesh MDLs in late stages. Bard $184M jury verdict in 2022 set the benchmark. Settlement framework discussions ongoing. New filing window narrowing.",
  "body": "Multiple hernia mesh MDLs in late stages. Bard $184M jury verdict in 2022 set the benchmark. Settlement framework discussions ongoing. New filing window narrowing.",
  "tortSignalScore": 67,
  "opportunityScore": 58,
  "riskScore": 42,
  "mdl": "MDL 2846 (S.D. Ohio)",
  "docket": "MDL 2846 (S.D. Ohio)",
  "drugName": "Hernia Mesh",
  "defendant": "Bard, Atrium, Ethicon, Covidien",
  "primaryInjury": "Mesh failure, infection, organ perforation, chronic pain",
  "jurisdictionLead": "Southern Ohio",
  "stage": "late",
  "campaign": "CLOSING",
  "caseValueRange": "$60K – $200K per qualifying claim",
  "litigationStatus": "MDL 2846 (Bard) and related dockets in active settlement negotiations. New filings still accepted but window closing.",
  "attorneyAction": "Time-sensitive. Focus on documented revision surgery cases. Avoid speculative pain-only claims.",
  "qualifies": "Patients implanted with polypropylene hernia mesh (Bard, Atrium C-QUR, Ethicon Physiomesh) who experienced revision surgery, infection, or chronic pain.",
  "competition": "high",
  "recentNews": [
    {
      "date": "Apr 09, 2026",
      "source": "Law360",
      "headline": "Bard hernia mesh settlement framework reaches $1.2B threshold"
    },
    {
      "date": "Apr 01, 2026",
      "source": "Reuters",
      "headline": "Ethicon Physiomesh MDL approaches global resolution"
    }
  ],
  "faq": [
    {
      "q": "What is the hernia mesh lawsuit about?",
      "a": "Plaintiffs allege defective polypropylene hernia mesh products caused mesh migration, organ perforation, infection, and chronic pain requiring revision surgery."
    },
    {
      "q": "Who qualifies?",
      "a": "Patients implanted with Bard, Atrium C-QUR, or Ethicon Physiomesh products who underwent revision surgery or experienced documented infection or chronic pain."
    },
    {
      "q": "What is the case value?",
      "a": "Qualifying claims are valued between $60,000 and $200,000 depending on injury severity and revision history."
    },
    {
      "q": "What is the litigation status?",
      "a": "MDL 2846 is in active settlement negotiations. A $1.2B Bard framework is reportedly nearing final approval."
    },
    {
      "q": "What should attorneys do?",
      "a": "Move quickly — the new-filing window is narrowing. Focus on documented revision surgery cases and avoid speculative pain-only claims."
    }
  ],
  "publisher": {
    "name": "LawTegic Solutions Media",
    "brand": "TortSignal",
    "url": "https://tortsignals.lawtegic.solutions"
  },
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "updatedAt": "2026-06-18T21:14:13.325Z"
}